Anacor Pharma (ANAC) Misses Q4 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. AAPL
3. REGN
4. LITE
5. ABBV
6. MRVL
7. PLTR
8. CL
9. LYB
10. TFII

Go back to Anacor Pharma (ANAC) Misses Q4 EPS by 13c

Anacor Pharmaceuticals Reports 2015 Fourth Quarter and Year-End Financial Results

February 29, 2016 4:01 PM EST

Submitted NDA to the FDA on January 7, 2016 seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory PDE-4 inhibitor in development for the potential treatment of mild-to-moderate atopic dermatitis in children and adults Recognized $69.7 million in total KERYDIN® distribution and commercialization agreement revenues for the year ended December 31, 2015

PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced its financial results for the fourth quarter and year ended December 31, 2015.

The past year has been very productive... More